VBI Vaccines @VBIVaccines
(Nasdaq: $VBIV) (TSX: $VBV) Provides
Update on its Congenital #CMV Phase I Clinical Study
Positive Safety Review and Final
Vaccination of All Participants
CAMBRIDGE,
MA (May 2, 2017) – (Investorideas.com Newswire) VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV)
(“VBI”) today provided an update on its cytomegalovirus (“CMV”) Phase I
clinical study, which is assessing the safety and tolerability of VBI’s vaccine
candidate to prevent congenital CMV infection. Congenital CMV infection is a leading
cause of birth defects, affecting more live births than Down syndrome or fetal
alcohol syndrome, making it a key public health priority.
Upon
review of all safety data up to one month after second immunizations in VBI’s prophylactic
CMV Phase I clinical study, the Data and Safety Monitoring Board (“DSMB”)
unanimously recommended the continuation of the study without modification. No
safety signals have been detected, suggesting VBI’s CMV vaccine candidate is
safe and well-tolerated.
Additionally,
all participants in the study have now successfully received the third and
final immunization in the series. Further vaccine immunogenicity and safety
follow-up are ongoing.
An
interim safety and immunogenicity report, based on blood samples collected from
participants one month post-second vaccination, is expected mid-year
2017.
Read this release in
full at http://www.investorideas.com/news/2017/biotech/05021VBIV.asp
About the Phase I
Clinical Study Design
The
Phase I study is designed to assess the safety and tolerability of VBI’s CMV
vaccine candidate in approximately 125 healthy CMV-negative adults. The study
will also determine the vaccine immunogenicity by measuring levels of
vaccine-induced CMV neutralizing antibodies, which may prevent CMV infection.
Additional
information, including a detailed description of the study design, eligibility
criteria, and investigator sites, is available at ClinicalTrials.gov
using identifier NCT02826798.
About the Data and
Safety Monitoring Board
The
DSMB was formed with key opinion leaders, a statistician, and experts in safety
in clinical studies of this nature. The board is an arms-length committee that
monitors the clinical study to assess safety data at various time points during
the clinical study, and to recommend to VBI whether to continue, modify, or
stop the study.
About CMV
CMV can cause
serious disease in newborns when a mother is infected during pregnancy. Each
year, approximately 5,000 U.S. infants will develop permanent problems due to
CMV, which can include deafness, blindness, and mental retardation. CMV affects
more live births than Down syndrome or fetal alcohol syndrome, making it a
key public health priority and a strong candidate for recommended universal
vaccination and reimbursement.
About VBI Vaccines
Inc.
VBI
Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company
developing a next generation of vaccines to address unmet needs in infectious
disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a
hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the
hepatitis B virus; Sci-B-Vac™ is approved for use in Israel and 14 other
countries. VBI’s eVLP Platform technology enables the development of enveloped
(“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus
to elicit a potent immune response. VBI is advancing a pipeline of eVLP
vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma
multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a
proprietary formulation and process that allows vaccines and biologics to
preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA
with research operations in Ottawa, Canada and research and manufacturing
facilities in Rehovot, Israel.
VBI Contact
Perri
Maduri, Communications Executive
Phone:
(617) 830-3031
VBI Investor
Contact
Nell
Beattie
Director,
Corporate Development and Investor Relations
Cautionary Statement
on Forward-looking Information
Certain statements
in this news release contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 or forward-looking
information under applicable Canadian securities legislation (collectively,
“forward-looking statements”) that may not be based on historical fact, but
instead relate to future events, including without limitation statements
containing the words “may”, “plan”, “will”, “suggesting”, “expected”, and
similar expressions. All statements other than statements of historical fact
included in this release are forward-looking statements, including statements
regarding: plans for Phase III clinical studies, the provision of additional
information about clinical studies, the safety and tolerability of the
congenital CMV vaccine candidate, the provision of an interim safety and
immunogenicity report, and the potential effects of Sci-B-Vac™.
Such forward-looking
statements are based on a number of assumptions, including assumptions
regarding the successful development and/or commercialization of the company’s
products, including the receipt of necessary regulatory approvals; general
economic conditions; competitive conditions; and changes in applicable laws, rules
and regulations.
Although management
believes that the assumptions made and expectations represented by such
statements are reasonable, there can be no assurance that a forward-looking
statement contained herein will prove to be accurate. Actual results and
developments may differ materially from those expressed or implied by the
forward-looking statements contained herein and even if such actual results and
developments are realized or substantially realized, there can be no assurance
that they will have the expected consequences or effects. Factors which could
cause actual results to differ materially from current expectations include:
the failure to successfully develop or commercialize the company’s products;
adverse changes in general economic conditions or applicable laws, rules and
regulations; and other factors detailed from time to time in the company’s
reports filed with the U.S Securities and Exchange Commission and the Canadian
Securities Commissions.
Given these risks,
uncertainties and factors, you are cautioned not to place undue reliance on
such forward-looking statements and information, which are qualified in their
entirety by this cautionary statement. All forward-looking statements and
information made herein are based on the company’s current expectations, and
the company undertakes no obligation to revise or update such forward-looking
statements and information to reflect subsequent events or circumstances,
except as required by law.
Disclaimer/Disclosure: Investorideas.com is a digital
publisher of third party sourced news, articles and equity research as well as
creates original content, including video, interviews and articles. Original
content created by investorideas is protected by copyright laws other than
syndication rights. Our site does not make recommendations for purchases or
sale of stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure – the following is a
paid news release for VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV)
Learn more about our newswire .
pricing and how to publish your news- http://www.investorideas.com/News-Upload/
Additional
info regarding BC Residents and global Investors: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to
regulations of each country.
No comments:
Post a Comment